A common test for investors is finding companies with solid, basic business expansion that are also at a point on the chart, ready for a possible price change. One method to manage this is to search for stocks displaying good basic expansion and sound finances while also showing a hopeful chart pattern, like a period of sideways movement close to a push higher. This method tries to match a company's shown operational speed with a positive market formation, possibly spotting chances before a major price direction forms.
Neurocrine Biosciences Inc (NASDAQ:NBIX) offers a situation that fits this investment idea. As a biopharmaceutical company centered on neuroscience, its sold products and research plans aim at neurological and neuroendocrine conditions, a field with large long-term expansion possibility.
Basic Strength: The Source for Expansion
The base of this method depends on finding companies with the monetary capacity to maintain expansion. Neurocrine's basic picture, as shown in its ChartMill Basic Analysis Report, displays notable force in important areas needed for an expansion stock.
- High Expansion Measures: The company gets a high Expansion Rating of 8/10. Over the last year, it has reported a notable 41.64% expansion in Earnings Per Share (EPS) and a 21.45% rise in Revenue. More significantly, this is not a single event; the average yearly EPS expansion over recent years is a solid 29.09%.
- Strong Earnings and Margins: With an Earnings Rating of 7/10, Neurocrine works effectively. Its Profit Margin of 16.73% and Operating Margin of 22.25% place in the high group of the competitive biotechnology field, showing it successfully turns revenue into profit.
- Firm Financial Soundness: A Soundness Rating of 7/10 points to a steady balance sheet. A particularly clear force is the company's total absence of debt, giving great monetary room and protecting it from interest rate changes. Its Altman-Z score of 7.24 indicates a very small near-term chance of failure.
These basic traits, consistent expansion, high earnings, and a balance sheet with no debt, are exactly what the search process looks for. They give the qualitative and numerical proof that the company's expansion is actual, maintainable, and built on a safe monetary base, which is necessary for any stock expected to do well over time.
Price Context
While expansion and soundness are ranked first, price gives context. Neurocrine's Price Rating is a middle 7/10, showing a varied picture. Its Price-to-Earnings (P/E) ratio of 27.55 is about equal to the wider S&P 500. However, when measured against its biotech field peers, which often sell at high prices due to expansion hopes, Neurocrine seems somewhat low in price. Its forward P/E ratio of 17.53 and Enterprise Value/EBITDA ratio cost less than over 94% of its field rivals. This hints the market may not be completely valuing its expansion path next to field standards, possibly giving a chance.
Chart Pattern: The Possible Trigger
A good basic story needs a positive chart view to indicate a possible point of entry. This is where the "pattern" part of the method is relevant. According to Neurocrine's ChartMill Chart Analysis Report, the stock now shows a Pattern Rating of 7/10, which is significant given its generally negative short- and long-term direction ratings.
The chart report notes that the stock has been moving sideways in an area between about $122 and $143 over the last month, with price swings reducing, a common sign before a big move. The stock is now trading near the bottom of this area, above a set support zone between $123.10 and $124.17. This period of movement above clear support, after a time of falling, can show a leveling pattern where selling is taken in.
Also, the report mentions more activity from bigger traders ("Effective Volume") in recent days, which can be a sign of institutional buying. For an expansion investor, this chart pattern is key because it finds a point where the stock's negative speed may be pausing and a turn, driven by its good basics, could be getting ready to start. The method suggests that a push above the sideways resistance could mark the beginning of a new rising direction.
Final Points and View
Neurocrine Biosciences shows a notable contrast: a company with clearly good basic expansion and financial soundness is now in a chart situation that often comes before a price move. The method of mixing these filters aims to find stocks where the basic reason for expansion is clear, and the chart is making the timing formation for a possible move.
While the wider market directions for the stock stay difficult, the mix of field-leading earnings, operations with no debt, maintained high-rate expansion, and a helpful chart pattern near support makes NBIX a stock deserving of more study for investors looking at expansion chances.
Want to find other stocks that fit this picture of good expansion and hopeful chart patterns? You can use the same search with our Good Expansion Stock Chart Patterns Search Tool.
Disclaimer: This article is for information only and is not financial guidance, a suggestion, or a bid to buy or sell any securities. The information shown is from given data and should not be the only base for any investment choice. Investing has risk, including the chance of losing the original amount. Always do your own study and think about talking with a registered financial advisor before making any investment choices.